Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

CYCN Relative to the S&P 500

CYCN Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Cyclerion Therapeutics Inc. (NASD:CYCN) seasonal charts above shows that a Buy Date of November 18 and a Sell Date of February 9 has resulted in a geometric average return of 29.69% above the benchmark rate of the S&P 500 Total Return Index over the past 5 years. This seasonal timeframe has shown positive results compared to the benchmark in 4 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 5 years by an average of 79.02% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 5 years of data is available for shares of CYCN, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

To download CYCN seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: CYCN